30 closest matches · ranked by relevance
Adult Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia · Therapy-Related Acute Myeloid Leukemia
Primary: Rate of Complete Remission and Mortality in the Entire Cohort of Older Patients — 21.9; 52.0 percentage of subjects
Novo Acute Myeloid Leukemia
Primary: Complete Remission of the Disease — NA; 18; 16; NA Participants
Leukemia · AML · MDS
Primary: Participants With a Complete Response — 34 Participants
Acute Myelogenous Leukemia
Primary: Percentage of Participants With Relapse Free Survival at 1 Year — 56 percentage of participants
Relapsed Acute Myeloid Leukemia
Primary: Feasibility of a Novel Combination of Pembrolizumab and Decitabine in Relapsed/Refractory Acute Myeloid Leukemia Participants — 10 Participants
Leukemia, Myeloid, Acute
Primary: Phase I Only - Maximum Tolerated Dose (MTD) as Measured by Dose-limiting Toxicities (DLTs) — 1; 0; 0 dose-limiting toxicities
Adult Acute Myeloid Leukemia · Adult Myelodysplastic Syndrome
Primary: Rate of Hospital Admission During Outpatient Induction Chemotherapy — 3; 14 Participants
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Leukemia, Myelocytic, Acute
Primary: Minimal Residual Disease (MRD). — 31; 43; 68; 63 participants — p=.1559
Acute Myeloid Leukemia
Primary: Peak Aerobic Capacity (VO2peak) — 6.9; 7.4 metabolic equivalent (METS)
Acute Myeloid Leukemia
Primary: Complete Response = Morphologic Complete Remission (mCR) — 13 Participants
Leukemia, Myelomonocytic, Acute
Primary: Overall Response Rate (Defined as Partial Remission or Better) to 3 Months of Treatment With Erlotinib — 0 percentage of participants
Leukemia, Myeloid, Acute
Primary: Phase I Only: Optimal Dose of AMD3100 Plus MEC in Patients With Relapsed or Refractory AML — 240 mcg/kg
Leukemia, Myelocytic, Acute
Primary: Probability of Disease-free Survival (DFS) at 6 Months Post-transplant (Death or Relapse Will be Considered Events for This Endpoint) — 81.8 percentage of patients
Acute Myelogenous Leukemia · High-Grade Myelodysplastic Syndrome
Primary: Best Overall Response Rate (ORR) Based on Investigator's Assessment — 6; 0; 1; 0 participants
Leukemia, Myeloid, Acute
Primary: Complete Remission Rate (CRm + CRi + CRc) — 0; 3; 0; 4 participants
Acute Myeloid Leukemia
Primary: Number of Patients With 2-year Relapse Risk — 10 Participants
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS)
Primary: Percentage Analyzed Participants Receiving Hematopoietic Stem Cell Transplantation (HCT) — 44.7 % participants
Leukemia, Myeloid
Primary: Response Rate (CR + CRi + LFS) — 3; 10 participants
Acute Myeloid Leukemia
Primary: Occurrence of Dose Limiting Toxicities — 0; 0; 0 participants
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
Leukemia
Primary: Efficacy of GM-CSF and Pegylated Interferon-alpha 2b When Administered to Patients With AML, ALL, Blast Phase CML, and MDS Relapse After Allogeneic Transplantation…
Leukemia · Acute Myeloid Leukemia · AML
Primary: Complete Response (CR) Rate — 98; 4; 9; 7 Participants
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Complete Response — 10 Participants
Acute Myeloid Leukemia
Primary: Overall Survival in Patients 65 Years or Older Who Have Newly Diagnosed de Novo or Secondary AML. — 5.0; 7.7 months — p=0.1079
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Complete Response Rate — 76; 24 participants
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Del(5q) · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Rate of Complete Remission — 25 patients
AML
Primary: Complete Response Rate — 19 Participants
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 45 participants